<SUBMISSION>
<ACCESSION-NUMBER>0000920148-00-000031
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20000608
<ITEMS>5
<ITEMS>7
<FILING-DATE>20000612
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>LABORATORY CORP OF AMERICA HOLDINGS
<CIK>0000920148
<ASSIGNED-SIC>8071
<IRS-NUMBER>133757370
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-11353
<FILM-NUMBER>653389
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>358 S MAIN ST
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
<PHONE>3362291127
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>358 S MAIN ST
<STREET2>4225 EXECUTIVE SQUARE, SUITE 800
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>NATIONAL HEALTH LABORATORIES HOLDINGS INC
<DATE-CHANGED>19940314
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.txt
<TEXT>




      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
                        JUNE 8, 2000
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission         (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                    Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)


<PAGE>

ITEM 5. OTHER EVENTS

  On  June  8,  2000,  Laboratory  Corporation  of  America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-
)  announced  that  its Board of Directors  has  declared  a
dividend  of  $0.08264 per share on the Company's  Series  A
Preferred  Stock,  payable  in cash.   The  Board  has  also
declared  a dividend of $0.08264 per share on the  Company's
Series  B  Preferred Stock, payable in shares  of  Series  B
Preferred Stock at the rate of 0.001653 shares per share  of
Series B Preferred Stock held. The dividends will be paid on
June  30,  2000  for  each issued and outstanding  share  of
Series  A  and  Series B Preferred Stock to stockholders  of
record  on  June 14, 2000 (whether or not such  stockholders
convert  their shares after such date), and will  cover  the
seven  days to July 7, 2000, the date set for redemption  of
the  Series A and Series B Preferred Stock, at an equivalent
annualized rate of $4.25 per share.  The dividends  will  be
paid  in  addition to the dividends payable on the Series  A
and  Series  B  Preferred Stock for the  quarterly  dividend
period  ended June 30, 2000 announced by the Company on  May
2, 2000.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      20  Press release of the Company dated
          June 8, 2000.

<PAGE>

                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                         (Registrant)

               By:/s/ BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: June 12, 2000

<PAGE>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-20
<SEQUENCE>2
<FILENAME>0002.txt
<TEXT>

Laboratory Corporation of America-Registered Trademark-Holdings
358 South Main Street
Burlington, NC   27215
Telephone:  336-584-5171

FOR IMMEDIATE RELEASE

Contact:  336-436-4855                  Shareholder Direct: 800-LAB-0401
          Pamela Sherry                                     www.labcorp.com

   LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK- DECLARES
                   FINAL PREFERRED STOCK DIVIDENDS

Burlington, NC, June 8, 2000 - Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-) (NYSE:
LH) today announced that its Board of Directors has declared a
dividend of $0.08264 per share on the Company's Series A Preferred
Stock, payable in cash.  The Board has also declared a dividend of
$0.08264 per share on the Company's Series B Preferred Stock, payable
in shares of Series B Preferred Stock at the rate of 0.001653 shares
per share of Series B Preferred Stock held.  No fractional shares of
Series B Preferred Stock will be issued, so that the number of shares
to be paid as a dividend on the Series B Preferred Stock will be
rounded to the nearest whole number of shares.  The dividends will be
paid on June 30, 2000, for each issued and outstanding share of
Series A and Series B Preferred Stock to stockholders of record on
June 14, 2000 (whether or not such stockholders convert their shares
after such date), and will cover the seven days to July 7, 2000, the
date set for redemption of the Series A and Series B Preferred Stock,
at an equivalent annualized rate of $4.25 per share.  The dividends
will be paid in addition to the dividends payable on the Series A and
Series B Preferred Stock for the quarterly dividend period ended June
30, 2000 announced by the Company on May 2, 2000.

Laboratory Corporation of America-Registered Trademark- Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory
with annual revenues of $1.7 billion in 1999.  With 18,000 employees
and over 100,000 clients nationwide, the Company offers more than
2,000 clinical tests ranging from simple blood analyses to
sophisticated molecular diagnostics. LabCorp leverages its expertise
in innovative clinical testing technology with three Centers of
Excellence. The Center for Molecular Biology and Pathology, in
Research Triangle Park (RTP), North Carolina, develops applications
for polymerase chain reaction (PCR) technology. Its Center for
Occupational Testing in RTP is the world's largest substance abuse
testing facility, and the Center for Esoteric Testing in Burlington,
North Carolina, performs the largest volume of specialty testing in
the network.  LabCorp's clients include physicians, state and federal
government, managed care organizations, hospitals, clinics,
pharmaceutical and Fortune 1000 companies, and other clinical
laboratories.
_______________________________
</TEXT>
</DOCUMENT>
</SUBMISSION>
